ProGenosis - Hybrid Proteins Platform

The main benefits of the BHP technology platform

  1. The exogenous polypeptide is displayed within a protein environment, which mimics wild-type protein constraints. It is often more difficult to achieve the same feature with fused peptides or chemical conjugations.
  2. Due to the fact that the technology enables an actual gene insertion and not a fusion, the folding of both the exogenous polypeptide and the enzyme scaffold are strongly inter-dependent. Consequently, the correct folding of the enzyme scaffold, and hence its biological activity, is conditioned by the correct folding of the exogenous polypeptide of interest.
  3. BHP technology uses a very robust and efficient positive drug-based screening system, which enables the easy and straightforward selection of fully soluble and well-folded BHPs. The β-lactamase enzyme enables bacteria to become resistant to antibiotics. Thus, when a bacterium fails to produce a soluble or active BHP, it dies in the presence of an antibiotic.
  4. The proprietary scaffold (29 kDa) exhibits a highly permissive ability. The molecular weight of successful insertions ranges from 2 kDa up to 40 kDa. This occurs without suffering the loss of either the enzymatic activity of the scaffold or the biological activity of the exogenous polypeptide. We strongly believe that the β-lactamase scaffold could accommodate even larger inserts.
  5. BHP technology is especially relevant for the cost-efficient expression of proteins that are difficult to produce, thanks to the use of the positive selection system, as only soluble BHPs will be produced efficiently.